William Looney

William Looney speaks to Dr. Claudia Graeve, who leads the Healthcare Businesswomen's Association's sole international chapter in Europe, on improving the prospects for female managers in the region.

Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.

Pharm Exec's Emerging Pharma Leaders 2013

Pharma jumps on board personal genomics train-at least for test drive-but will journey ultimately help transform treatment or stall out as just another fad?

South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.

Breaking down the four steps to a successful drug launch, using Keryx Biopharmaceuticals’ model for Auryxia, its new treatment for chronic kidney disease.

This year's J.P. Morgan Conference in San Francisco showed that smaller “stealth pharma” players are beginning to show solid organic growth. William Looney reports.

The small biotech space-credited with ending the drought in new FDA drug approvals in recent years-takes center stage at this year's J.P. Morgan Investors Conference.

Pharma is still a 21st Century growth industry, but investment dynamics no longer favor organic growth. Check out our strategic outlook infographic.

I offered up a prediction: that the future of the biopharmaceutical business depended on how managers fared on five key measures of performance.

Pharm Exec profiles Sanofi EVP Pascale Witz, tagged with the assignment to move a lumbering biopharma giant closer to the embrace of the patient perspective in healthcare.

AmerisourceBergen, big Pharma’s top distribution partner, looks to build on its US success in healthcare delivery to create a global service mix focused on knowledge transfer, scale and reach, and partnered innovation.

THE CALENDAR SAYS IT'S WRAP UP TIME, not just for gifts, but for some of the trends that shaped big Pharma-for good or bad-during the past year. A simple way to close the book on 2014 is to draw some insights from our three feature stories this month.

Two words define the future of commercialization project management: Faster and Better

Pharm Exec profiles Express Scripts' Chief Medical Officer, Dr. Steve Miller, whose rise to prominence as an articulate critic of drug industry prices symbolizes the growing clout of America's largest pharmacy benefit manager.

Amid a resurgence in drug development for hard-to-treat conditions, the bigger question is whether the times are as good for the industry tasked with rendering basic science into therapeutically effective medicines.

Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.

The US is skewing young again, and the "millennials" have the clout to color everything from the nation's cultural landscape to the conduct of business practices like marketing and customer engagement, writes Bill Looney.

Pharm Exec‘s 13th Industry Audit looks at how well a cross section of companies in big Pharma, mid-tier specialty and biotech are delivering against today’s hottest performance metric: shareholder value.

Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value.

Michael Injaychock joined Eli Lilly in 2007 after five years in a Washington-based financial services consulting role and a subsequent MBA from the University of North Carolina.

Mid-career students at Brown University’s new Executive Masters in Healthcare Leadership program are challenging the status quo with workplace projects focused on one thing: removing the organizational silos that slow innovations in the delivery and financing of healthcare.

Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success, writes William Looney.

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed- small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up.

Today’s vaccines business represents an almost perfect world for big Pharma. There is a vast landscape of unmet medical need; lots of new science.

A surprising take away from the BIO International Convention in San Diego last month is the stark contrast between cooperative industry engagement and an unstable geopolitical order marked by xenophobia,

As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead for M&A, licensing, and partnership activity.

A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.

Is the FDA doing enough to incorporate the patient perspective in the drug review process? This was the key question considered at a panel of regulatory experts held at last month’s annual BIO International Convention in San Diego.